Compare Quest Diagnostics Inc (DGX) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Toronto-Dominion Bank — how do they compare? Quest Diagnostics Inc trades at $236.93 (market cap $26.21B), while Toronto-Dominion Bank trades at $123.07 (market cap $200.48B). The key difference: Toronto-Dominion Bank is far larger — about 7.6× Quest Diagnostics Inc's market cap, and Toronto-Dominion Bank pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| DGX | TD | |
|---|---|---|
Market Cap | $26.21B | $200.48B |
Sector | Health | Financials |
52-Week High | $238.50 | $124.80 |
52-Week Low | $173.49 | $72.85 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
TD trades at $121.08, down 0.19% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.70. Revenue grew to $61.28 billion in 2025, and net income margin improved to 33.51%. A dividend of $1.12 is scheduled for payment on July 31, 2026.
The outlook is positive given consistent earnings outperformance and a solid dividend, but risks include high debt levels and volatile cash flows. Analyst consensus is bullish with no sell ratings, supporting a favorable medium-term view amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
